Page last updated: 2024-11-02

pd 169316 and Parkinson Disease

pd 169316 has been researched along with Parkinson Disease in 1 studies

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oh, CK1
Han, BS1
Choi, WS1
Youdim, MB1
Oh, YJ1

Other Studies

1 other study available for pd 169316 and Parkinson Disease

ArticleYear
Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration.
    Apoptosis : an international journal on programmed cell death, 2011, Volume: 16, Issue:11

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 2; Caspase Inhibitors; Cell Line; Cytochrome

2011